Found 29 matching trials
Bcl-2 Inhibitor GDC-0199 in Combination With Obinutuzumab and Ibrutinib in Treating Patients With Relapsed, Refractory, or Previously Untreated Chronic Lymphocytic Leukemia PHASE1 This phase Ib/II trial studies the best dose and safety of Bcl-2 inhibitor ...
Show More Status
Active Not Recruiting
Location
Ohio State University Comprehensive Cancer Center
Learn More & Join Trial
Epcoritamab Plus Venetoclax Plus Ibrutinib in Patients With Chronic Lymphocytic Leukemia With TP53 Alterations PHASE2 This is a phase 2, open-label, multicenter study evaluating the efficacy an...
Show More Location
Institut Jules Bordet
Learn More & Join Trial
Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL PHASE1 The purpose of this study is to determine the optimal dosing scheme for the...
Show More Learn More & Join Trial
The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell Lymphoma EARLY_PHASE1 The purpose of this study is to test the safety of Venetoclax in combinatio...
Show More Location
Memorial Sloan Kettering Basking Ridge
Learn More & Join Trial
A Study to Evaluate Efficacy & Safety of Obinutuzumab, Ibrutinib, and Venetoclax in Richter's Syndrome; PHASE2 Richter's syndrome (RS) is a life-threatening complication of chronic lymph...
Show More Location
Bnai Zion Medical Center
Learn More & Join Trial
Study of the Use of Venetoclax in Participants With Chronic Lymphocytic Leukemia (CLL) Under Real-Life Setting N/A An observational study to assess the effectiveness, health economic-relevan...
Show More Location
Universitaetsklinikum St. Poelten /ID# 221152
Learn More & Join Trial
Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma PHASE1 Background:
Aggressive B-cell lymphomas can be cured but people with disea...
Show More Status
Active Not Recruiting
Location
National Institutes of Health Clinical Center
Learn More & Join Trial
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia PHASE3 This phase III trial studies how well ibrutinib and obinutuzumab with or wi...
Show More Status
Active Not Recruiting
Location
University of Alabama at Birmingham Cancer Center
Learn More & Join Trial
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma PHASE1 Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in c...
Show More Location
University of California San Diego
Learn More & Join Trial
Genetically Risk-Stratified Venetoclax, Ibrutinib, Rituximab (± Navitoclax) in Relapsed/Refractory Mantle Cell Lymphoma PHASE2 This is an open label, multi-centre, phase II study in which RR MCL patient...
Show More Status
Active Not Recruiting
Location
Princess Alexandra Hospital
Learn More & Join Trial